Status:
COMPLETED
A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
65-85 years
Phase:
PHASE1
Brief Summary
The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.
Detailed Description
Evaluation of cognitive function
Eligibility Criteria
Inclusion
- Adult healthy volunteers 65 years and over with minimum MMSE of 26
Exclusion
- Prohibited concomitant medications
- Confounding medical conditions
- Clinically significant comorbid diseases
- Hypersensitivity or contraindications to fesoterodine or active control
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01161472
Start Date
July 1 2010
End Date
September 1 2010
Last Update
June 28 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Overland Park, Kansas, United States, 66211
2
Pfizer Investigational Site
Overland Park, Kansas, United States, 66212